Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
577
Frequently Asked Questions
What is Market Cap of Arcus Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Arcus Biosciences Inc market cap is $1.41B.
What is the 52-week high for Arcus Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Arcus Biosciences Inc 52 week high is $25.47 as of June 08, 2024.
What is the 52-week low for Arcus Biosciences Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Arcus Biosciences Inc 52 week low is $12.95 as of June 08, 2024.
What is Arcus Biosciences Inc stock price today?
Arcus Biosciences Inc stock price today is $15.50.
What was Arcus Biosciences Inc stock price yesterday?
Arcus Biosciences Inc stock price yesterday was $15.90.
What is the PE ratio of Arcus Biosciences Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Arcus Biosciences Inc’s P/E ratio is -5.00.
What is the Price-to-Book ratio of Arcus Biosciences Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Arcus Biosciences Inc P/B ratio is 1.9929.
What is Arcus Biosciences Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Arcus Biosciences Inc's EBITDA is -2.74.
What is the 50-day moving average of Arcus Biosciences Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Arcus Biosciences Inc 50-day moving average is $16.23.
How many employess does Arcus Biosciences Inc has?